Effects of Treatment with L-thyroxin on Glucose Regulation in Patients with Subclinical Hypothyroidism
Edina Bilic-Komarica, Amela Beciragic, Dzelaludin Junuzovic
Med Arh. 2012; 66(6): 364-368
Aims: We examined effects of treatment with l-thyroxin on glucose regulation in patients with subclinical hypothyroidism. Methods: The study included 100 patients, ages 51.75±13.23 years, BMI=27.97±4.52 kg/m2, with SH (TSH>4.2 mU/L and with normal level of T3 and T4). Laboratory evaluation included serum free T3, free T4, TSH, thyroid antibodies, TGL, insulin, C-peptide and glucose during OGTT, HbA1c, CRP and level of lipids. Percentile, average and correlation analysis have been utilized in statistical analysis. Twelve patients with SH had GI and 38 patients had DM. All patients were treated with low dose of l-thyroxin (25-50ug) and high physical activity. Results: After 6 months treatment with l-thyroxin, patients had normal or limited TSH (5.85±0.92 vs. 3.54±0.55 mU/L), level of fasting insulin (114.64±24.11 vs. 96.44±17.26 pmol/l) significantly decreased, HbA1c (6.74±1.01 vs. 6.26±1.12) decreased as well. The level of CRP significantly decreased as well (2.27±0.8 vs. 3.32±1.1 mg/l). The changes were and in level of total cholesterol (5.39±0.57 vs. 6.10±0.67 mmol/l), triglyceride levels (1.69±0.37 vs. 2.22±0.49 mmol/l), HDL cholesterol (1.16±0.14 vs. 1.03±0.15mmol/l) and LDL cholesterol (3.79±0.64 vs. 4.37±0.77 mmol/l). The correlation between TSH and HbA1c was positive and significant (r=0.46). Conclusion: The normalization of TSH resulted in decrease of level of fasting insulin, fasting and postprandial glucose, CRP and lipids. Higher CRP associated with fasting hyperinsulinemia before insulin resistance has been evidenced in most patients with SH. These data support an important role of treatment of SH in support of glucose regulation.
1. Beciragic A, Bilic-Komarica E, Junuzovic Dz. The Importance of HbA1C Control in Patients with Subclinical Hypothireoidism. Mat Soc Med Dec; 24(4): 212-219.
2. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004; 291(2): 228-238.
3. Kvetny J, Heldgaard PE, Bladbjerg EM, Gram J. Subclinical hypothyroidismis associated with alow-grade inflammation, increased triglyceride elevel sand predicts cardiovascular disease inmales below 50 years Clin Endocrinol. 2004; 61: 232-238.
4. Imaizumi M, Akahoshi M, Ichimaru S, et al. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism J Clin Endocrinol Metab. 2004; 89: 3365-3370.
5. Radaideh A, El-Khateeb M, Batieha AM, Nasser AS, Ajlouni KM. Thyroid function and thyroid autoimmunity in patients with type 1 Diabetes mellitus. Saudi Med J. 2003; 24(4):352-355.
6. Heljić B. Diabetes mellitus. U: Heljić B, Dilić M, Čengić M, Čengić F, Lončarević N. Diabetes mellitus – klinički aspekti. Sarajevo, Jež, 2002; 16-26.
7. Sayeda Al, Alin Al, Boabbas Y. Subclinical hypodhyroidism in associated with early insulin resistence in Kuwaiti women. Endocrine J. 2006; 53:5: 653-657.
8. Gavran L, Zildzic M, Batic-Mujanovic O, Alic A, Gledo I, Prasko S. Auditing of Medical Chart Among Type 2 Diabetic Patient Done by Primary Care Physicians. Med Arh. 2012; 66(6): 388-390.
9. Nakamura T, Adachi H, Hirai Y, et al. Association of Plasminogen Activator Inhibitor-1 With Insulin Resistance in Japan Where Obesity is Rare. Metabolism. 2003; 52: 226-229.
10. De Groot LJ, Quintans J. The causes of autoimune thyroid disease. Endocrin Rev. 1989; 10: 537.
11. Diez JJ, Iglesias P, Burman KD. Spontaneous normalization of thyrotropin concentations in patients with subclinical hypothyreoidism. J Clin Endocrinol Metab. 2005, 90: 4124-4127.
12. Beyhan Z, Erturk K, Uckaya G, Bolu E, Yaman H, Kutlu M. Restoration of euthyroidism does not improve cardiovascular risk factors in patients with subclinical hypothyroidism in the short term. Journal of Endocrinological Investigation. 2006; 29(6): 505-510.
13. AACE, American Association of Clinical Endocrinologists. Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hyperthyroidism and Hypothyroidism, Endocrine Practice. 2002; 8: 457-469.
14. Perros P, Mc Crimmon R, Shaw G, Frier B. Frequency of thyroid dysfunction in diabetic patients: value of annual screening. Diabet Med. 1995; 7: 622-627.
15. Tulloch B, Lewis B, Russell-Fraser T. Triglyceride metabolism in thyroid disease. Lancet. 1973; 1: 391-394.
16. Bahceci M, Tuzcu A, Ogun C, Canoruc N, Iltimir K, Aslan C. Is serum C-reactive protein concentration correlated with HbA1c and isulin resistence in type 2 diabetic men with or xithout disease? J Endocrinol Invest. 2005; 28(2): 145.
17. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes? Curr Des. 2010; 16(34): 3939-3947.
18. Jusufovic S, Hodzic E, Halilcevic A. Role of Renal Anemia in the Functional, Morphological and Autoimune Thyroid Disorders in Patients on Chronic Hemodialysis. Med Arh. 2011; 65(4): 228-232.
19. Jusufovic S, Hodzic E. Role of Chronic Hemodialysis in Thyroid Gland Morphology Disorders. Med Arh. 2011; 65(6): 327-329.
20. Godinjak A, Godinjak Z, Burekovic A, Surkovic I, Dizdarevic-Bostandzic A, Velija-Asimi Z. Insulin Resistence and Lipid Accumulation Product in Correlation to Body Mass Index in Women with Polycystic Ovary Syndrome. Med Arh. 2012; 66(6): 409-411.
21. Jusufovic S, Hodzic E. Funtional Thyroid Disorders are More Common in Patients on Chronic Hemodialysis Compared with the General Population. Mat Soc Med. 2011; 23(4): 206-209.